High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohnʼs disease: A marker for patient classification?

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease

(2011) L. S. Kiss et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease

(2011) Matthias Jürgens et al.   Clinical Gastroenterology and Hepatology

Correlation Between the Crohn's Disease Activity and Harvey–Bradshaw Indices in Assessing Crohn's Disease Severity

(2010) Severine Vermeire et al.   Clinical Gastroenterology and Hepatology

Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohnʼs disease

(2010) Peter Laszlo Lakatos et al.   INFLAMMATORY BOWEL DISEASES

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis

(2010) Gert Van Assche et al.   Journal of Crohns & Colitis

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Is the disease course predictable in inflammatory bowel diseases?

(2010) Peter Laszlo Lakatos   WORLD JOURNAL OF GASTROENTEROLOGY

Fecal Calprotectin Correlates More Closely With the Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, Blood Leukocytes and the CDAI

(2009) Alain M Schoepfer et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohnʼs disease

(2009) Geert R. DʼHaens et al.   INFLAMMATORY BOWEL DISEASES

Relationships Between Disease Activity and Serum and Fecal Biomarkers in Patients With Crohn's Disease

(2008) Jennifer Jones et al.   Clinical Gastroenterology and Hepatology